Opportunity
Obesity, characterized by hypertrophy and hyperproliferation of adipose tissue, is a major global health concern and a significant risk factor for numerous diseases, including dyslipidemia, cardiovascular disease, type 2 diabetes, and cancer. At the cellular level, obesity involves deregulation of adipogenesis—the process where pre-adipocytes differentiate into mature adipocytes. Interestingly, mature adipocytes are not terminally static; they possess plasticity and can revert to a multipotent progenitor-like state through a process called dedifferentiation. This phenomenon is observed in physiological contexts like lactation and in pathological conditions such as tumor development. Harnessing adipocyte dedifferentiation holds immense promise for regenerative medicine, as dedifferentiated fat cells (DFAT cells) can potentially be redirected to form other cell types for tissue repair. However, existing methods to induce dedifferentiation, such as "ceiling culture" or applying physical stressors like hypertonicity, lack a clear understanding of the underlying molecular mechanisms. Specifically, while hypertonic treatment is known to induce dedifferentiation and involves the activation of the anti-adipogenic Wnt/β-catenin signaling pathway, the precise link between osmotic stress and this pathway activation remained elusive. This knowledge gap limits the ability to develop efficient, controlled, and clinically viable strategies for generating multipotent cells from abundant adipose tissue. The present patent addresses this critical need by elucidating the novel molecular axis connecting hypertonic stress to adipocyte reprogramming.
Technology
The present invention provides a method for inducing dedifferentiation of adipocytes by elucidating and leveraging a novel signaling pathway. The core innovation involves subjecting adipocytes (e.g., 3T3-L1 or stromal vascular fraction-derived cells) to a hypertonic solution, typically culture medium supplemented with 2% PEG 300. This osmotic stress triggers a specific cellular response: it induces the release of mitochondrial extracellular vesicles (MEVs) from the adipocytes into the extracellular environment. These released MEVs are not passive byproducts; they function in an autocrine manner. The invention discovers that these MEVs enhance the secretion of a series of inflammatory genes, most notably Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-6 (IL-6). This pro-inflammatory signaling, in turn, is essential for activating the Wnt/β-catenin signaling pathway. The activation of this pathway—evidenced by the stabilization and nuclear accumulation of β-catenin—is the direct driver of adipocyte dedifferentiation. The technology further identifies that direct pharmacological activation of the Wnt/β-catenin pathway using a small molecule compound like BML-284 can efficiently induce dedifferentiation while circumventing the apoptotic side effects associated with prolonged hypertonic treatment. Thus, the invention defines a complete mechanistic axis: Hypertonicity → Mitochondrial Stress → MEV Release → TNF-α secretion → Wnt/β-catenin activation → Adipocyte Dedifferentiation.
Advantages
- Provides a clear molecular mechanism linking hypertonic stress to adipocyte dedifferentiation via the novel mitochondria-TNF-α-Wnt/β-catenin axis.
- Offers a relatively simple and controllable in vitro method to generate dedifferentiated, multipotent progenitor-like cells from mature adipocytes.
- Identifies mitochondrial extracellular vesicles (MEVs) as key signaling mediators, opening new avenues for research in cellular communication and stress response.
- Demonstrates that direct activation of Wnt/β-catenin signaling (e.g., with BML-284) can induce dedifferentiation more efficiently and without the apoptosis induced by extended hypertonic treatment.
- Establishes a robust cellular model using common adipocyte lines (3T3-L1) and primary cells, facilitating reproducible research.
- The generated dedifferentiated adipocytes retain the capacity for osteogenic and chondrogenic re-differentiation, confirming their multipotency.
Applications
- Regenerative Medicine & Tissue Engineering: Production of multipotent DFAT cells for potential use in repairing bone, cartilage, or other mesenchymal tissues.
- Drug Discovery & Screening: Utilizing the hypertonicity-induced MEV release model or the dedifferentiation process to screen for compounds that modulate adipocyte plasticity, Wnt signaling, or mitochondrial function.
- Disease Modeling: Studying the role of adipocyte dedifferentiation in disease contexts such as obesity, metabolic syndrome, and cancer (e.g., understanding the adipocyte mesenchymal transition in tumor microenvironments).
- Basic Cell Biology Research: Investigating mechanisms of cellular plasticity, mitochondrial quality control via EV release, and cross-talk between inflammatory signaling and developmental pathways like Wnt/β-catenin.
- Biomarker Development: MEVs released under hypertonic stress could be studied as potential biomarkers for cellular stress or metabolic disorders.
